🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareFDA compounding enforcement update — June 2026 guidance document Page 2

FDA compounding enforcement update — June 2026 guidance document

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 156 replies 34,261 viewsPage 2 of 20
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Feb 26, 2024 at 6:50 PM#6

Saving this for reference. Top-tier content.

47 12NicoleRaleigh, james_edin, FranDenver and 44 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Feb 26, 2024 at 7:07 PM#7

Slightly tangential to FDA compounding but TinaHashiRN reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Last edited: Feb 26, 2024 at 10:07 PM
23 12tane_welly, Dr.PathRoch, mona_PHX and 20 others
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Feb 26, 2024 at 7:24 PM#8

+1 to TinaHashiRN. Especially the point about "A few questions about your FDA compoundi..." — I have seen the same in my own experience with FDA compounding.

25 13TomTeleRx, DoseLogDan, SleepFixSam and 22 others
Reply Quote Save Share Report
BrianDallas92
Member
312
1,456
Oct 2024
Dallas, TX
Feb 26, 2024 at 7:41 PM#9

Dr.LipidDallas — that is really helpful context on FDA compounding. Follow-up question: how long did you wait before increasing your dose?

I am in a similar situation (week 4) and trying to set realistic expectations.

2 18Dr.EndoEP, GraceAZ_72
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Feb 26, 2024 at 7:58 PM#10

To answer gary_naperville's question specifically:

From a clinical standpoint, FDA compounding enforcement is a reasonable concern that deserves a thorough answer.

The short answer: the evidence supports this approach for most patients.

The longer answer involves reviewing the specific clinical trial data relevant to your question, which I am happy to elaborate on if helpful.

32 14maria_elpaso, anders_CPH, Dr.NutriCornell and 29 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register